AGIO,ELVN Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +1.47
Percentage change 4.36	%

Peers: AMGN REGN VRTX GILD ALNY SRPT NBIX BLUE FOLD NVAX

| Held by: VTI IWM VB VXF VBK XBI IWN IBB SCHA VTWO

Index	RUT	P/E	3.09	EPS (ttm)	11.40	Insider Own	3.66%	Shs Outstand	57.16M	Perf Week	5.77%
Market Cap	2.02B	Forward P/E	-	EPS next Y	-5.98	Insider Trans	-2.34%	Shs Float	55.20M	Perf Month	3.41%
Income	673.73M	PEG	-	EPS next Q	-1.76	Inst Own	106.81%	Short Float	9.11%	Perf Quarter	-33.41%
Sales	36.50M	P/S	55.29	EPS this Y	-163.23%	Inst Trans	3.28%	Short Ratio	5.85	Perf Half Y	-21.51%
Book/sh	26.96	P/B	1.31	EPS next Y	18.77%	ROA	51.82%	Short Interest	5.03M	Perf Year	29.96%
Cash/sh	15.60	P/C	2.26	EPS next 5Y	-	ROE	57.29%	52W Range	26.50 - 62.58	Perf YTD	7.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	42.61%	52W High	-43.72%	Beta	0.91
Dividend TTM	-	Quick Ratio	11.56	Sales past 5Y	4.89%	Gross Margin	73.10%	52W Low	32.91%	ATR (14)	1.56
Dividend Ex-Date	-	Current Ratio	11.90	EPS Y/Y TTM	286.86%	Oper. Margin	-1166.47%	RSI (14)	54.02	Volatility	4.20% 4.24%
Employees	488	Debt/Eq	0.04	Sales Y/Y TTM	36.07%	Profit Margin	1845.92%	Recom	1.50	Target Price	56.67
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	1.60%	Payout	0.00%	Rel Volume	1.18	Prev Close	33.75
Sales Surprise	14.15%	EPS Surprise	14.83%	Sales Q/Q	51.06%	Earnings	Feb 13 BMO	Avg Volume	859.77K	Price	35.22
SMA20	4.07%	SMA50	0.00%	SMA200	-17.85%	Trades		Volume	1,018,352	Change	4.36%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-10-24	Resumed	Raymond James	Outperform	$51
Sep-27-24	Downgrade	Leerink Partners	Outperform → Market Perform	$60 → $56
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight	$41
Nov-17-22	Upgrade	Goldman	Sell → Neutral	$17 → $32
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$33
Dec-03-21	Initiated	BofA Securities	Buy	$54
Jul-30-21	Downgrade	Goldman	Neutral → Sell	$58 → $39
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy	$88
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$50
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral	$64 → $54
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight	$46
Mar-04-20	Initiated	Barclays	Equal Weight	$50
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight	$64
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy	$55
May-23-19	Resumed	Goldman	Neutral	$55
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$80

Show Previous Ratings

Feb-20-25 07:00AM	Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 (GlobeNewswire)
Feb-15-25 10:05AM	Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank (TipRanks)
Feb-14-25 02:09AM	Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Feb-13-25 12:45PM	Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:31AM	Loading…
06:31AM	Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
06:30AM	Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint (GlobeNewswire)
Feb-12-25 10:25AM	Agios Pharmaceuticals price target lowered to $54 from $55 at BofA (TipRanks)
08:05AM	Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-06-25 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 (GlobeNewswire)
Jan-13-25 04:29PM	Why Agios Pharmaceuticals (AGIO) Is the Top Small Cap Stock to Buy with the Highest Upside Potential (Insider Monkey)
07:00AM	Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio (GlobeNewswire)
Jan-08-25 07:00AM	FDA Accepts Agios' Supplemental New Drug Application for PYRUKYND (mitapivat) in Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire)
Jan-03-25 10:00AM	How to Navigate the Stock and Bond Markets in 2025 (The Wall Street Journal)
07:00AM	Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
07:00AM	Loading…
Dec-18-24 07:00AM	European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease (GlobeNewswire) -7.01%
Dec-10-24 09:39AM	Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank (TipRanks) -5.39%
Dec-09-24 04:21PM	Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug (Investor's Business Daily) -21.09%
Dec-08-24 12:40PM	Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat (GlobeNewswire)
Dec-05-24 08:42AM	Are Options Traders Betting on a Big Move in Agios (AGIO) Stock? (Zacks)
Nov-26-24 09:40AM	Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-05-24 09:05AM	Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
Nov-01-24 03:03AM	Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Oct-31-24 07:45AM	Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates (Zacks)
06:42AM	Agios Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Agios Reports Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-23-24 07:00AM	Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease (GlobeNewswire)
Oct-17-24 07:00AM	Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Sep-27-24 10:34AM	Do Options Traders Know Something About Agios (AGIO) Stock We Don't? (Zacks) -5.08%
Sep-26-24 04:05PM	Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. (Investor's Business Daily)
07:56AM	Loading…
Sep-17-24 07:56AM	Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results (Insider Monkey)
Sep-12-24 06:33AM	Agios Pharmaceuticals tebapivat gains FDA orphan drug designation (Pharmaceutical Technology)
Sep-11-24 07:00AM	Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) (GlobeNewswire)
Sep-05-24 07:00AM	Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 (GlobeNewswire)
Aug-09-24 07:50AM	Agios Pharmaceuticals, Inc. (AGIO): Are Street Analysts Bullish on This Top Caligan Partner Holding Right Now? (Insider Monkey)
07:23AM	Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now? (Insider Monkey)
Aug-06-24 05:50PM	Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib (GlobeNewswire)
Aug-01-24 01:42PM	Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides (Benzinga)
07:45AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:43AM	Agios Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:31AM	Agios Reports Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
06:30AM	Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused (GlobeNewswire)
Jul-25-24 10:01AM	Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-24 07:00AM	Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jun-24-24 04:25AM	Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains? (Zacks)
Jun-15-24 08:45AM	Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress (GlobeNewswire)
Jun-07-24 07:00PM	Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Jun-06-24 09:00AM	Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ET (GlobeNewswire)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
Jun-04-24 12:44PM	Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study (Zacks) +8.03%
Jun-03-24 06:30AM	Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia (GlobeNewswire) +20.61%
May-30-24 04:05PM	Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (GlobeNewswire)
May-29-24 12:35PM	Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty (Zacks)
May-28-24 04:03PM	Agios Breaks Out On 'Buffed Up' Financials After Inking Massive Brain Cancer Deal (Investor's Business Daily) +23.21%
12:20PM	Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 (Associated Press Finance)
09:46AM	Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out (Investor's Business Daily)
08:12AM	Agios cashes in on cancer drug again with $905M Royalty Pharma deal (BioPharma Dive)
07:00AM	Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty (GlobeNewswire)
May-24-24 09:55AM	How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43% (Zacks)
May-14-24 10:00AM	Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress (GlobeNewswire)
May-08-24 09:55AM	Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High? (Zacks)
May-06-24 07:00AM	Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024 (GlobeNewswire)
May-03-24 12:21PM	Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates (Zacks)
11:10AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00AM	Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024 (GlobeNewswire)
03:03AM	Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 10:45PM	Q1 2024 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
12:57PM	Agios Pharmaceuticals Shares Rise After Reporting Smaller Q1 Loss (MT Newswires)
11:56AM	AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:44AM	Agios Pharmaceuticals Reports Q1 2024 Earnings: Narrower Loss than Expected with Strong Revenue ... (GuruFocus.com)
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:29AM	Agios Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Agios Reports Business Highlights and First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 10:02AM	Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-18-24 07:00AM	Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 (GlobeNewswire)
Apr-16-24 04:30PM	The 3 Best Biotech Stocks to Buy Now: Q2 Edition (InvestorPlace)
Apr-10-24 07:01PM	Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Apr-09-24 07:00AM	Agios Publishes 2024 Environmental, Social and Governance (ESG) Report (GlobeNewswire) +7.26%
Mar-05-24 07:00AM	Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024 (GlobeNewswire)
Feb-26-24 03:12PM	Agios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS Rating (Investor's Business Daily)
Feb-23-24 10:45AM	Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark (Investor's Business Daily) +10.78%
Feb-22-24 07:00AM	Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024 (GlobeNewswire) +11.12%
Feb-20-24 08:24AM	Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-16-24 09:38AM	Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates (Zacks)
Feb-15-24 10:15PM	Q4 2023 Agios Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
08:25AM	Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:59AM	Agios Pharmaceuticals Inc (AGIO) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-08-24 10:00AM	Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline (Zacks)
Feb-02-24 07:00AM	Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024 (GlobeNewswire)
Jan-24-24 07:02PM	Agios Pharmaceuticals Inc Director Jacqualyn Fouse Sells 10,722 Shares (GuruFocus.com) +8.88%
Jan-11-24 07:15PM	Insider Sell: CEO Brian Goff Sells 12,066 Shares of Agios Pharmaceuticals Inc (AGIO) (GuruFocus.com)
Jan-08-24 07:00AM	Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio (GlobeNewswire) +5.66%
Jan-04-24 11:19AM	Agios (AGIO) Up 5% on Upbeat Data From Thalassemia Study (Zacks)
07:47AM	Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock? (Zacks)
Jan-03-24 04:05PM	Agios Stock Whipsaws As It Looks To Rival Crispr, Vertex In A Key Market (Investor's Business Daily) +5.21%
02:46PM	Biotech Stocks Dyne, Agios Leap on Muscle-Disorder Drugs' Trial Results (The Wall Street Journal)
02:01PM	Biotechs Dyne, Agios Leap on Muscle-Disorder Drugs Trial Results (The Wall Street Journal)
10:09AM	Agios Pharma Surged, And Then Pulled Back, After Testing A Thalassemia Drug (Investor's Business Daily)
09:26AM	Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug (Investor's Business Daily)

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 01 '25	Option Exercise	0.00	6,896	0	7,709	Feb 05 04:02 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Feb 05 '25	Sale	34.39	2,272	78,134	5,437	Feb 05 04:02 PM
Milanova Tsveta	Chief Commercial Officer	Jan 03 '25	Option Exercise	0.00	8,476	0	21,710	Jan 07 05:05 PM
Milanova Tsveta	Chief Commercial Officer	Jan 06 '25	Sale	32.18	2,804	90,233	18,906	Jan 07 05:05 PM
Milanova Tsveta	Officer	Jan 03 '25	Proposed Sale	31.84	2,804	89,279		Jan 03 04:25 PM
Scadden David	Director	Dec 11 '24	Option Exercise	18.09	200	3,618	15,683	Dec 13 04:04 PM
Scadden David	Director	Dec 11 '24	Sale	46.28	200	9,256	15,483	Dec 13 04:04 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Nov 08 '24	Sale	56.09	772	43,301	813	Nov 13 04:14 PM
Ballal Rahul D.	Director	Nov 07 '24	Option Exercise	25.99	10,000	259,900	17,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 08 '24	Option Exercise	25.99	10,000	259,900	17,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 08 '24	Sale	58.19	10,000	581,911	7,992	Nov 12 04:09 PM
Ballal Rahul D.	Director	Nov 07 '24	Sale	53.52	10,000	535,236	7,992	Nov 12 04:09 PM
Burns James William	Chief Legal Officer	Nov 07 '24	Sale	52.21	21,752	1,135,775	15,700	Nov 12 04:08 PM
RAHUL BALLAL	Director	Nov 08 '24	Proposed Sale	58.19	10,000	581,894		Nov 08 04:17 PM
RAHUL BALLAL	Director	Nov 07 '24	Proposed Sale	53.52	10,000	535,241		Nov 07 04:51 PM
JAMES BURNS	Officer	Nov 07 '24	Proposed Sale	52.21	21,752	1,135,711		Nov 07 04:06 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '24	Option Exercise	0.00	7,473	0	22,700	Sep 30 04:15 PM
Jones Cecilia	Chief Financial Officer	Sep 26 '24	Sale	49.03	2,542	124,634	20,158	Sep 30 04:15 PM
Ballal Rahul D.	Director	Aug 11 '24	Option Exercise	0.00	2,302	0	7,992	Aug 13 04:15 PM
Smith Cynthia	Director	Aug 11 '24	Option Exercise	0.00	2,302	0	7,992	Aug 13 04:12 PM
Goff Brian	Chief Executive Officer	Aug 08 '24	Option Exercise	0.00	22,691	0	89,883	Aug 12 05:15 PM
Goff Brian	Chief Executive Officer	Aug 08 '24	Sale	42.75	11,091	474,140	78,792	Aug 12 05:15 PM
Goff Brian	Officer	Aug 08 '24	Proposed Sale	42.75	11,091	474,184		Aug 08 04:08 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '24	Option Exercise	0.00	8,375	0	47,441	Jul 03 04:30 PM
Gheuens Sarah	Chief Medical Officer	Jul 01 '24	Sale	43.85	3,705	162,464	43,736	Jul 03 04:30 PM
Foster-Cheek Kaye I	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	8,912	Jun 17 05:32 PM
FOUSE JACQUALYN A	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	140,784	Jun 17 05:31 PM
Schenkein David P	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	126,242	Jun 17 05:29 PM
Ballal Rahul D.	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	5,690	Jun 17 05:22 PM
Smith Cynthia	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	5,690	Jun 17 05:20 PM
Ho Maykin	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	14,912	Jun 17 05:19 PM
Scadden David	Director	Jun 13 '24	Option Exercise	0.00	3,388	0	15,483	Jun 17 05:18 PM
Owen Catherine E.	Director	Jun 13 '24	Option Exercise	0.00	1,976	0	1,976	Jun 17 05:15 PM
CAPELLO JEFFREY D	Director	Jun 13 '24	Option Exercise	0.00	1,976	0	1,976	Jun 17 05:13 PM
Goff Brian	Chief Executive Officer	Jun 05 '24	Option Exercise	0.00	25,527	0	79,307	Jun 07 04:25 PM
Goff Brian	Chief Executive Officer	Jun 05 '24	Sale	48.84	12,115	591,697	67,192	Jun 07 04:25 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Jun 03 '24	Sale	44.39	1,362	60,459	1,524	Jun 05 04:14 PM
FOUSE JACQUALYN A	Director	Apr 08 '24	Option Exercise	0.00	15,934	0	145,187	Apr 10 04:03 PM
FOUSE JACQUALYN A	Director	Apr 10 '24	Sale	27.55	7,791	214,642	137,396	Apr 10 04:03 PM
Foster-Cheek Kaye I	Director	Mar 07 '24	Sale	31.62	1,285	40,632	5,524	Mar 11 04:09 PM
Foster-Cheek Kaye I	Director	Mar 06 '24	Sale	31.99	4,415	141,236	6,809	Mar 07 06:49 PM
Foster-Cheek Kaye I	Director	Mar 05 '24	Sale	32.21	300	9,663	11,224	Mar 07 06:49 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 05 '24	Sale	31.75	1,913	60,738	2,886	Mar 07 06:47 PM
Gheuens Sarah	Chief Medical Officer	Mar 01 '24	Option Exercise	0.00	7,834	0	40,415	Mar 05 04:20 PM
Gheuens Sarah	Chief Medical Officer	Mar 05 '24	Sale	32.57	2,642	86,050	36,415	Mar 05 04:20 PM
Jones Cecilia	Chief Financial Officer	Mar 01 '24	Option Exercise	0.00	2,000	0	15,512	Mar 05 04:18 PM
Jones Cecilia	Chief Financial Officer	Mar 05 '24	Sale	32.57	672	21,887	14,840	Mar 05 04:18 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 01 '24	Option Exercise	0.00	3,127	0	5,718	Mar 05 04:15 PM
Washburn Theodore James Jr.	Principal Accounting Officer	Mar 05 '24	Sale	32.57	1,214	39,540	3,368	Mar 05 04:15 PM
Goff Brian	Chief Executive Officer	Mar 01 '24	Option Exercise	0.00	8,500	0	57,936	Mar 05 04:10 PM
Goff Brian	Chief Executive Officer	Mar 05 '24	Sale	32.57	4,156	135,361	53,780	Mar 05 04:10 PM
Burns James William	Chief Legal Officer	Mar 01 '24	Option Exercise	0.00	7,834	0	38,518	Mar 05 04:08 PM
Burns James William	Chief Legal Officer	Mar 05 '24	Sale	32.57	2,642	86,050	34,518	Mar 05 04:08 PM
Schenkein David P	Director	Feb 27 '24	Option Exercise	31.64	69,329	2,193,570	180,325	Feb 29 04:05 PM
Schenkein David P	Director	Feb 27 '24	Sale	34.67	69,329	2,403,592	122,854	Feb 29 04:05 PM
Schenkein David P	Director	Feb 23 '24	Option Exercise	31.64	47,731	1,510,209	170,585	Feb 27 04:04 PM
Schenkein David P	Director	Feb 26 '24	Option Exercise	31.64	20,411	645,804	143,265	Feb 27 04:04 PM
Schenkein David P	Director	Feb 23 '24	Sale	33.05	47,731	1,577,510	122,854	Feb 27 04:04 PM
Schenkein David P	Director	Feb 26 '24	Sale	33.19	20,411	677,441	122,854	Feb 27 04:04 PM

Dollar change +0.33
Percentage change 1.54	%

ELVN Enliven Therapeutics Inc daily Stock Chart

Peers: REGN VRTX ALNY IONS BMRN INCY NBIX PRTA EXEL ONC

| Held by: VTI IWM VXF IWO IBB VTWO SCHA IWC VHT IHE

Index	RUT	P/E	-	EPS (ttm)	-1.91	Insider Own	35.38%	Shs Outstand	47.25M	Perf Week	1.40%
Market Cap	1.07B	Forward P/E	-	EPS next Y	-2.28	Insider Trans	-1.32%	Shs Float	31.57M	Perf Month	-1.13%
Income	-85.21M	PEG	-	EPS next Q	-0.51	Inst Own	73.05%	Short Float	22.52%	Perf Quarter	-12.45%
Sales	0.00M	P/S	-	EPS this Y	3.17%	Inst Trans	7.30%	Short Ratio	32.53	Perf Half Y	-2.24%
Book/sh	6.10	P/B	3.57	EPS next Y	-17.28%	ROA	-29.41%	Short Interest	7.11M	Perf Year	31.56%
Cash/sh	5.97	P/C	3.65	EPS next 5Y	-9.63%	ROE	-30.98%	52W Range	10.90 - 30.03	Perf YTD	-3.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.16%	ROI	-29.55%	52W High	-27.41%	Beta	1.02
Dividend TTM	-	Quick Ratio	17.44	Sales past 5Y	0.00%	Gross Margin	-	52W Low	100.00%	ATR (14)	1.13
Dividend Ex-Date	-	Current Ratio	17.44	EPS Y/Y TTM	-159.81%	Oper. Margin	-	RSI (14)	48.03	Volatility	3.84% 4.55%
Employees	46	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	37.71
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	5.24%	Payout	-	Rel Volume	0.78	Prev Close	21.47
Sales Surprise	-	EPS Surprise	3.40%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	218.55K	Price	21.80
SMA20	0.35%	SMA50	-2.87%	SMA200	-8.17%	Trades		Volume	169,970	Change	1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Initiated	BTIG Research	Buy	$42
Sep-09-24	Initiated	H.C. Wainwright	Buy	$37
Jun-11-24	Initiated	Robert W. Baird	Outperform	$32
Apr-09-24	Initiated	Mizuho	Buy	$34
Mar-29-23	Initiated	Jefferies	Buy	$27

Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
04:52AM	Loading…
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
10:54PM	Loading…
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
06:40AM	Loading…
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 05:02 PM
Patel Anish	Member of immediate family of	Feb 14 '25	Proposed Sale	21.50	2,500	53,750		Feb 14 04:17 PM
Patel Anish	CHIEF OPERATING OFFICER	Feb 07 '25	Sale	21.93	6,667	146,206	329,977	Feb 10 05:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 05 '25	Option Exercise	2.48	1,000	2,480	14,000	Feb 07 07:06 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Feb 05 '25	Sale	22.52	1,000	22,524	13,000	Feb 07 07:06 PM
Patel Anish	Officer	Feb 07 '25	Proposed Sale	22.47	6,667	149,807		Feb 07 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 27 '25	Option Exercise	2.48	3,250	8,060	16,250	Jan 29 07:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 27 '25	Sale	21.59	3,250	70,178	13,000	Jan 29 07:21 PM
Hohl Benjamin	Officer	Jan 27 '25	Proposed Sale	21.86	4,250	92,905		Jan 27 04:37 PM
Patel Anish	Member of immediate family of	Jan 14 '25	Proposed Sale	22.07	2,500	55,175		Jan 14 04:06 PM
Patel Anish	Member of immediate family of	Jan 14 '25	Proposed Sale	22.07	2,500	55,175		Jan 14 04:01 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Option Exercise	1.81	21,700	39,264	21,700	Jan 10 05:31 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Sale	24.18	21,700	524,697	0	Jan 10 05:31 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 07 '25	Sale	24.17	6,667	161,171	336,644	Jan 10 05:31 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 13 '24	Option Exercise	2.48	13,000	32,240	13,000	Jan 07 04:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 03 '25	Option Exercise	2.48	1,000	2,480	14,000	Jan 07 04:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jan 03 '25	Sale	25.04	1,000	25,039	13,000	Jan 07 04:43 PM
Patel Anish	Officer	Jan 07 '25	Proposed Sale	24.07	28,367	682,794		Jan 07 04:21 PM
Hohl Benjamin	Officer	Jan 03 '25	Proposed Sale	23.90	1,000	23,900		Jan 03 04:05 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 27 '24	Option Exercise	2.48	3,350	8,308	3,350	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 30 '24	Option Exercise	2.48	900	2,232	900	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 27 '24	Sale	22.15	3,350	74,219	0	Dec 31 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 30 '24	Sale	22.51	900	20,255	0	Dec 31 05:18 PM
Hohl Benjamin	Officer	Dec 27 '24	Proposed Sale	22.71	4,250	96,518		Dec 27 04:33 PM
Patel Anish	Member of immediate family of	Dec 16 '24	Proposed Sale	23.15	2,500	57,875		Dec 16 04:30 PM
Patel Anish	Member of immediate family of	Dec 16 '24	Proposed Sale	23.15	2,500	57,875		Dec 16 04:15 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Option Exercise	2.48	5,250	13,020	5,250	Dec 02 05:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Nov 27 '24	Sale	24.89	5,250	130,688	0	Dec 02 05:18 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:35 PM
Patel Anish	Member of immediate family of	Nov 15 '24	Proposed Sale	24.92	17,500	436,100		Nov 15 04:28 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Option Exercise	2.48	6,250	15,500	6,250	Oct 30 06:04 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 28 '24	Sale	28.56	6,250	178,485	0	Oct 30 06:04 PM
Patel Anish	CHIEF OPERATING OFFICER	Oct 18 '24	Sale	30.00	716	21,483	343,311	Oct 22 04:23 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 18 '24	Sale	30.00	847	25,413	1,015,188	Oct 22 04:22 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 18 '24	Sale	30.00	924	27,723	1,002,892	Oct 22 04:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Option Exercise	2.48	814	2,019	814	Oct 22 04:19 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 18 '24	Sale	30.00	814	24,422	0	Oct 22 04:19 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	817	24,512	123,673	Oct 22 04:18 PM
Heyman Richard A.	Director	Oct 18 '24	Sale	30.00	753	22,592	27,165	Oct 22 04:18 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 18 '24	Option Exercise	2.48	816	2,024	816	Oct 22 04:17 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 18 '24	Sale	30.00	816	24,482	0	Oct 22 04:17 PM
Patel Anish	Officer	Oct 18 '24	Proposed Sale	28.02	50,000	1,401,000		Oct 18 06:42 PM
Lyssikatos Joseph P	Officer	Oct 18 '24	Proposed Sale	28.02	65,000	1,821,300		Oct 18 05:42 PM
Heyman Richard A.	Director	Oct 18 '24	Proposed Sale	28.02	1,566	43,879		Oct 18 05:27 PM
Kintz Samuel	Officer	Oct 18 '24	Proposed Sale	28.02	91,123	2,553,266		Oct 18 05:17 PM
Heyman Richard A.	Director	Oct 18 '24	Proposed Sale	28.02	12,165	340,863		Oct 18 05:10 PM
Hohl Benjamin	Officer	Oct 18 '24	Proposed Sale	28.02	13,000	364,260		Oct 18 05:00 PM
Collins Helen Louise	Officer	Oct 18 '24	Proposed Sale	28.02	25,000	700,500		Oct 18 04:57 PM
Heyman Richard A.	Director	Oct 15 '24	Sale	27.67	1,270	35,143	124,490	Oct 17 05:06 PM
Heyman Richard A.	Director	Oct 15 '24	Proposed Sale	27.75	1,270	35,242		Oct 15 04:38 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 09 '24	Sale	28.16	37,878	1,066,561	1,016,035	Oct 10 08:39 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 08 '24	Sale	27.97	13,267	371,024	1,053,913	Oct 10 08:39 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 09 '24	Sale	28.15	16,710	470,405	1,003,816	Oct 10 08:38 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 08 '24	Sale	27.96	13,267	370,929	1,020,526	Oct 10 08:38 PM
Ballal Rahul D.	Director	Oct 08 '24	Option Exercise	14.10	10,420	146,925	32,761	Oct 10 08:36 PM
Ballal Rahul D.	Director	Oct 08 '24	Sale	28.17	10,420	293,557	22,341	Oct 10 08:36 PM
Lyssikatos Joseph P	Officer	Oct 09 '24	Proposed Sale	28.01	12,000	336,120		Oct 09 04:27 PM
Kintz Samuel	Officer	Oct 09 '24	Proposed Sale	28.01	12,000	336,120		Oct 09 04:16 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 04 '24	Sale	27.51	7,522	206,937	1,069,887	Oct 08 06:58 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 07 '24	Sale	27.61	2,707	74,727	1,067,180	Oct 08 06:58 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 04 '24	Sale	27.51	12,206	335,792	1,036,523	Oct 08 06:57 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 07 '24	Sale	27.50	2,730	75,075	1,033,793	Oct 08 06:57 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 04 '24	Option Exercise	2.48	10,218	25,341	10,218	Oct 08 06:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 07 '24	Option Exercise	2.48	1,270	3,150	2,000	Oct 08 06:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 04 '24	Sale	27.51	10,218	281,079	0	Oct 08 06:56 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 07 '24	Sale	27.51	1,270	34,935	0	Oct 08 06:56 PM
Heyman Richard A.	Director	Oct 04 '24	Sale	27.51	2,825	77,704	125,760	Oct 08 06:54 PM
Ballal Rahul D.	Director	Oct 08 '24	Proposed Sale	27.45	10,420	286,029		Oct 08 03:59 PM
Heyman Richard A.	Director	Oct 04 '24	Proposed Sale	25.51	2,540	64,795		Oct 04 04:28 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Oct 01 '24	Sale	27.54	527	14,512	1,077,409	Oct 03 06:47 PM
Kintz Samuel	PRESIDENT AND CEO	Oct 01 '24	Sale	27.54	526	14,485	1,048,729	Oct 03 06:45 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 01 '24	Option Exercise	2.48	521	1,292	521	Oct 03 06:44 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 01 '24	Sale	27.54	521	14,347	0	Oct 03 06:44 PM
Heyman Richard A.	Director	Oct 01 '24	Sale	27.54	518	14,264	128,585	Oct 03 06:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 27 '24	Option Exercise	2.48	4,250	10,540	4,250	Oct 01 07:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 30 '24	Option Exercise	2.48	2,000	4,960	2,000	Oct 01 07:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 27 '24	Sale	24.27	4,250	103,161	0	Oct 01 07:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 30 '24	Sale	25.33	2,000	50,668	0	Oct 01 07:53 PM
Hohl Benjamin	Officer	Oct 01 '24	Proposed Sale	25.54	12,009	306,710		Oct 01 04:14 PM
Hohl Benjamin	Officer	Sep 30 '24	Proposed Sale	24.13	491	11,848		Sep 30 04:19 PM
Heyman Richard A.	Director	Sep 16 '24	Sale	22.41	1,270	28,458	129,103	Sep 18 04:17 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Aug 29 '24	Sale	22.49	12,000	269,841	1,077,936	Sep 03 05:43 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '24	Option Exercise	2.48	4,250	10,540	4,250	Aug 29 06:36 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 27 '24	Sale	22.54	4,250	95,782	0	Aug 29 06:36 PM
Kintz Samuel	PRESIDENT AND CEO	Aug 26 '24	Sale	22.89	12,000	274,718	1,049,255	Aug 28 07:48 PM
Heyman Richard A.	Director	Aug 15 '24	Sale	23.25	1,270	29,526	130,373	Aug 19 07:49 PM
Kintz Samuel	Member of immediate family of	Aug 19 '24	Proposed Sale	23.71	30,000	711,300		Aug 19 04:32 PM
Kintz Samuel	Member of immediate family of	Aug 19 '24	Proposed Sale	23.71	30,000	711,300		Aug 19 04:32 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 31 '24	Sale	27.56	3,099	85,399	1,089,936	Aug 02 07:26 PM
Kintz Samuel	PRESIDENT AND CEO	Jul 31 '24	Sale	27.56	2,270	62,555	1,061,255	Aug 02 07:25 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 31 '24	Option Exercise	2.48	991	2,458	991	Aug 02 07:23 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 31 '24	Sale	27.53	991	27,281	0	Aug 02 07:23 PM
Heyman Richard A.	Director	Jul 31 '24	Sale	27.51	1,702	46,815	131,643	Aug 02 07:22 PM
Heyman Richard A.	Director	Jul 31 '24	Sale	27.50	649	17,848	27,918	Aug 02 07:22 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jul 29 '24	Sale	26.70	12,000	320,378	1,093,035	Jul 31 07:33 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Option Exercise	2.48	5,250	13,020	5,250	Jul 31 07:31 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 29 '24	Sale	26.68	5,250	140,052	0	Jul 31 07:31 PM
Heyman Richard A.	Director	Jul 31 '24	Proposed Sale	26.13	649	16,958		Jul 31 04:57 PM
Heyman Richard A.	Director	Jul 31 '24	Proposed Sale	26.13	5,045	131,826		Jul 31 04:31 PM
Hohl Benjamin	Officer	Jul 31 '24	Proposed Sale	26.13	11,000	287,430		Jul 31 04:30 PM

AGIO

Agios Pharmaceuticals Inc

ELVN

Enliven Therapeutics Inc

Upgrade your FINVIZ experience